Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The levels of NGAL and adiponectin were higher in LVAD recipients and patients with heart failure as compared with healthy controls.
|
30699407 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical and Humoral Determinants of Congestion in Heart Failure: Potential Role of Adiponectin.
|
31553971 |
2019 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated baseline circulating adiponectin level is possibly associated with an increased risk of all-cause mortality and the combined endpoints of death/readmission in patients with heart failure.
|
31314851 |
2019 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neither serum adiponectin nor ADIPOQ variants predicted HF.
|
29969725 |
2018 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> Adiponectin circulating levels were determined by ELISA at discharge in patients admitted for <i>de novo</i> HF (n=74).
|
29559829 |
2018 |
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with the highest baseline adiponectin concentration (quartile [Q]4) were at significantly higher risk of death from a CV event (8.4% vs 1.7%; P < .0001), hospitalization for heart failure (HF; 7.5% vs 1.7%; P < .0001), and all-cause mortality (10.8% vs 2.4%; P < .0001) compared with those in Q1.
|
28195387 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to evaluate the relationship between body mass index (BMI), leptin and adiponectin concentrations and prognosis in patients with heart failure due to non ischeamic dilated cardiomyopathy (NIDCM).
|
28255978 |
2017 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TT and eFT were independently determined by age, total fat mass and adiponectin levels in elderly men with HF (p < 0.05 for all).
|
28696825 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study shows that fenofibrate may protect against ET-1-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiac hypertrophy and heart failure.
|
27629528 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Role of Serum Adiponectin for Outcome Prediction in Patients with Dilated Cardiomyopathy and Advanced Heart Failure.
|
29318144 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
Heart failure
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to assess the relationship between p53 and adiponectin mRNA in epicardial adipose tissue (EAT) and subcutaneous adipose tissue (SAT) in patients with heart failure and its sympathetic regulation.
|
24117366 |
2014 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma BNP was the strongest predictor of circulating adiponectin and its release from all adipose tissue depots in patients with coronary artery bypass grafting, even in the absence of HF.
|
25060790 |
2014 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cox proportional hazards models adjusting for covariates in stages revealed that only baseline EAT adiponectin levels and heart failure could predict CV events.
|
22974530 |
2012 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mean (SD) age was 71.6 (9.6) years.Patients who met Adult Treatment Panel III MS criteria (n=29) presented lower plasma adiponectin concentrations (11.2 (7.4) vs. 19.6 (8.4) mg/l, P=0.004), lower EAT adiponectin mRNA (12.7 (3.0) vs. 15.1 (3.7) a.u., P=0.029) and similar SAT adiponectin mRNA levels (13.7 (4.2) vs. 15.6 (5.7) a.u., P=0.25) than those without MS. After adjusting for age, sex, CAD and heart failure, the association with MS remained statistically significant for plasma adiponectin (OR 0.862 (0.762-0.974)), was of borderline significance for EAT adiponectin mRNA (OR 0.796 (0.630-1.005)) and not significant for SAT adiponectin mRNA (OR 0.958 (0.818-1.122)).
|
21330150 |
2011 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Natriuretic peptides enhance adiponectin production by human adipocytes in vitro and even in patients with CHF, which might have a beneficial effect on cardiomyocytes in patients receiving recombinant natriuretic peptide therapy for heart failure.
|
19477358 |
2009 |
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
|
19367012 |
2009 |
Heart failure
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
|
19367012 |
2009 |